Drugs Containing Excipient (Inactive Ingredient) POLYETHYLENE TEREPHTHALATE

Branded drugs containing POLYETHYLENE TEREPHTHALATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hangzhou Fanhuo Network Technology Co Ltd	NIENJOY NICOTINE TRANSDERMAL SYSTEM	nienjoy nicotine transdermal system patch	84318-001	POLYETHYLENE TEREPHTHALATE

Generic drugs containing POLYETHYLENE TEREPHTHALATE excipient

Company	Ingredient	NDC	Excipient
Rhodes Pharmaceuticals LP	scopolamine	42858-150	POLYETHYLENE TEREPHTHALATE
Bryant Ranch Prepack	scopolamine	71335-3013	POLYETHYLENE TEREPHTHALATE
Bryant Ranch Prepack	scopolamine	71335-3014	POLYETHYLENE TEREPHTHALATE

Polyethylene Terephthalate in Pharmaceutical Packaging: Market Dynamics, Financial Trajectory, and Regulatory Position

Last updated: July 31, 2026

Polyethylene terephthalate, or PET, is primarily a pharmaceutical packaging material rather than a pharmaceutical excipient. It is used in bottles, blister components, closures, diagnostic containers, and other packaging systems. The commercial outlook depends on PET resin pricing, recycled-content regulation, pharmaceutical packaging demand, conversion capacity, and qualification requirements. Direct pharmaceutical revenue from PET is rarely disclosed because resin producers and packaging companies report broader segments.

Is polyethylene terephthalate a pharmaceutical excipient?

PET is generally not used as an active pharmaceutical ingredient or conventional formulation excipient. Its main pharmaceutical role is as a container or packaging component.

An excipient is an inactive substance incorporated into a drug product, such as a binder, filler, lubricant, preservative, or coating agent. PET is instead used to contain and protect the drug. The distinction affects regulatory treatment, quality documentation, extractables and leachables testing, and inclusion in product filings.

Attribute	PET in pharmaceutical packaging	Conventional pharmaceutical excipient
Primary function	Container, bottle, barrier, or packaging component	Formulation support
Direct contact	Often in direct contact with the drug	Incorporated into the dosage form
Regulatory focus	Container-closure suitability, migration, extractables and leachables	Identity, purity, functionality, safety
Typical supply chain	Resin producer to converter to packaging manufacturer	Excipient producer to drug manufacturer
Revenue disclosure	Usually embedded in packaging or polymer segments	Often reported by ingredient category
Main commercial risks	Resin prices, recycling rules, qualification changes	Formulation substitution, quality, regulatory status

The phrase “PET pharmaceutical excipient market” therefore overstates the size of the direct excipient opportunity. The relevant market is pharmaceutical PET packaging and medical-grade PET resin.

What pharmaceutical products use PET packaging?

PET is used most often for solid oral medicines, liquid oral products, nutraceuticals, diagnostic products, and selected healthcare applications.

Solid oral dosage forms

PET bottles are used for tablets, capsules, powders, and vitamins. The polymer provides low weight, impact resistance, transparency, and compatibility with high-speed filling operations. Pharmaceutical bottles may use PET with induction seals, child-resistant closures, desiccants, or oxygen-control systems.

Liquid medicines

PET is used for syrups, oral solutions, suspensions, and topical products. The formulation determines whether PET is suitable. High-risk products require testing for sorption, permeation, oxidation, hydrolysis, and migration.

Diagnostic and healthcare products

PET is also used for laboratory containers, specimen packaging, medical trays, and selected device components. These applications expand the addressable market beyond finished-dose pharmaceuticals but have different qualification and sterilization requirements.

Parenteral and biologic products

PET has a more limited role in direct primary packaging for injectable biologics and other sensitive products. Glass, cyclic olefin polymers, cyclic olefin copolymers, polypropylene, and specialized multilayer systems compete more directly in these applications.

Biologics impose stricter requirements for particulate control, protein adsorption, oxygen transmission, moisture transmission, and container closure integrity. PET may be used in secondary packaging or selected primary systems, but the qualification burden is higher than for many oral products.

What regulations apply to pharmaceutical PET?

PET packaging must comply with the applicable drug, food-contact, and material standards in the target jurisdiction. Regulatory acceptance is product-specific and depends on the formulation, contact conditions, manufacturing process, and intended shelf life.

United States FDA status

The FDA regulates PET packaging through food-contact regulations, drug container-closure requirements, and chemistry, manufacturing, and controls documentation. Title 21 of the Code of Federal Regulations includes provisions addressing polyethylene phthalate polymers for food-contact use, including 21 C.F.R. § 177.1630.

FDA approval of a PET resin grade does not automatically establish suitability for every drug product. A manufacturer must evaluate the complete container-closure system under actual or exaggerated storage conditions.

Relevant FDA expectations include:

• Material composition and supplier qualification
• Extractables and leachables assessment
• Container closure integrity
• Moisture and oxygen transmission
• Light protection where required
• Compatibility with the drug formulation
• Toxicological assessment of migrating substances
• Change-control documentation

The FDA Inactive Ingredient Database is not the appropriate primary reference for PET packaging because PET is generally not added to the formulation as an inactive ingredient. Packaging suitability is evaluated through the drug application and container-closure documentation.

USP and pharmacopeial standards

USP General Chapters <661.1> and <661.2> address plastic materials and plastic packaging systems used for pharmaceutical products. These chapters cover material characterization, biological reactivity, chemical testing, and performance-related considerations.

The European Pharmacopoeia and other national standards also address plastic materials, packaging systems, and migration risk. The applicable standard depends on the product market and packaging configuration.

How large is the pharmaceutical PET market?

The direct pharmaceutical PET market is not separately reported by most publicly traded resin or packaging companies. Published market studies usually combine pharmaceutical plastic packaging with healthcare packaging, or PET with other polymers.

A practical market-sizing framework is:

1. Estimate global pharmaceutical plastic packaging demand.
2. Identify the share represented by rigid PET containers and components.
3. Remove non-pharmaceutical healthcare uses.
4. Adjust for recycled PET, multilayer systems, closures, and conversion margins.
5. Separate resin value from packaging-system value.

The resin portion is generally a minority of the final pharmaceutical packaging price. Qualification, molding, printing, closure integration, inspection, sterilization, and documentation can account for a substantial portion of the converted package value.

Market layer	Main value drivers	Public reporting quality
PET resin	Paraxylene, monoethylene glycol, energy, freight, plant utilization	High at polymer-company segment level
Pharmaceutical-grade resin	Purity, consistency, documentation, qualification	Limited
Bottle conversion	Preform and bottle production, tooling, inspection	Limited
Finished packaging system	Closures, seals, labels, desiccants, testing	Moderate for packaging companies
Pharmaceutical end-market	Prescription and OTC volume, dosage form, geography	Usually reported by drug manufacturers

The highest-margin opportunity is usually not commodity PET resin. It is qualified packaging systems that have been approved by pharmaceutical customers and integrated into validated filling lines.

What drives PET pharmaceutical packaging demand?

Demand is tied to pharmaceutical volume, packaging format, regulatory requirements, and sustainability policy.

Growth in oral solid products

Tablets and capsules remain the largest demand base for rigid pharmaceutical packaging. Generic medicines, over-the-counter products, vitamins, and consumer health products use PET bottles because the material is light, durable, and compatible with automated filling.

Shift from glass to plastic in selected products

PET can replace glass where lower breakage, reduced shipping weight, and improved impact resistance matter. The substitution is limited by oxygen permeability, moisture sensitivity, solvent compatibility, and light-protection requirements.

E-commerce and distribution requirements

Direct-to-patient distribution increases demand for durable packaging and tamper evidence. PET’s impact resistance is favorable for parcel shipments, although packaging must still meet closure, labeling, and child-resistance requirements.

Sustainability regulation

Recycled PET, or rPET, is becoming more important. European packaging rules, extended producer responsibility programs, recycled-content mandates, and customer sustainability commitments are increasing demand for recycled feedstock.

Pharmaceutical adoption is slower than in beverage packaging because recycled material must meet tighter controls on traceability, contamination, color, consistency, and extractables. Virgin PET remains important for high-control primary packaging.

Supply-chain localization

Drug manufacturers and packaging buyers are increasing regional sourcing to reduce disruption risk. PET resin and preform production are geographically concentrated, so local or dual sourcing can influence supplier selection even when material cost is not the lowest.

What is the financial trajectory for PET producers and pharmaceutical packaging companies?

PET resin earnings are cyclical. Pharmaceutical packaging demand is more stable, but its growth does not eliminate exposure to commodity inputs.

Resin producers

PET producers are exposed to:

• Paraxylene and monoethylene glycol prices
• Natural gas and electricity costs
• Plant utilization and shutdowns
• Chinese capacity additions
• Freight and regional arbitrage
• Recycled PET availability
• Currency movements

When global capacity grows faster than demand, resin spreads contract. This can reduce profitability even when shipment volumes increase. Commodity PET producers therefore have a weaker earnings profile than specialized pharmaceutical packaging converters.

Packaging converters

Converters generally have better earnings visibility when they have:

• Long-term customer contracts
• Validated packaging platforms
• Proprietary preforms or bottle designs
• Integrated closure and inspection capabilities
• Regional manufacturing redundancy
• Documented extractables and leachables data
• High switching costs at pharmaceutical customers

The conversion business remains exposed to PET resin inflation, but contracts may permit pass-through. Margin performance depends on the timing of price adjustments and the share of value generated by services and specialized packaging.

Recycled PET suppliers

rPET suppliers face a different trajectory. Their economics depend on collection rates, bale prices, food-grade recycling capacity, energy costs, and regulatory credits. Pharmaceutical packaging creates a premium opportunity, but qualification requirements can slow adoption and raise conversion costs.

Relevant corporate participants

The competitive field includes resin producers, packaging converters, and diversified healthcare-packaging companies. Examples include Indorama Ventures, Alpek, Eastman, Amcor, Berry Global, Gerresheimer, AptarGroup, and selected regional bottle manufacturers. Their reported financial results do not isolate pharmaceutical PET revenue, so company-level exposure must be inferred from segment mix, product disclosures, and customer concentration.

How does PET compare with competing pharmaceutical packaging materials?

Material	Principal advantages	Principal limitations	Strongest pharmaceutical use
PET	Low weight, impact resistance, transparency, recyclability	Moisture and oxygen barrier below glass and some high-performance polymers	Oral solids, liquids, OTC products
HDPE	Strong moisture barrier, chemical resistance, established bottle platform	Less transparent, lower stiffness in some designs	Tablets, capsules, powders
Glass	High barrier, low permeability, established regulatory history	Breakage, weight, transport cost	Injectables, sensitive liquids
PP	Heat resistance, chemical resistance, low cost	Barrier and dimensional limitations	Bottles, closures, medical components
COP/COC	Low extractables, high clarity, strong barrier performance	Higher cost, limited supply base	Biologics, injectables, diagnostic systems
Aluminum	Excellent light and oxygen barrier	Corrosion and compatibility concerns	Tubes, blister structures, selected liquids

PET competes most directly with high-density polyethylene in oral solid packaging. PET has better appearance and impact performance; HDPE often has stronger moisture-barrier performance. The choice is formulation-specific.

What manufacturing and intellectual-property barriers affect PET packaging?

Manufacturing barriers are more significant than classical drug patent barriers.

Key barriers include:

• Resin-grade consistency
• Acetaldehyde and oligomer control
• Low particulate production
• Cleanroom molding and filling compatibility
• Preform and bottle tooling
• Container closure integrity
• Extractables and leachables datasets
• Child-resistant and tamper-evident design
• Recycled-content qualification
• Supplier audit history
• Regulatory change control

PET itself is a mature polymer with extensive public-domain chemistry. Competitive differentiation is more likely to arise from bottle geometry, multilayer structures, barrier coatings, recycled-content processing, manufacturing equipment, inspection systems, and packaging designs than from broad composition patents.

Pharmaceutical customers may also create de facto exclusivity through validated packaging specifications. A converter does not need a blocking patent to maintain commercial protection if switching suppliers would require stability studies, line requalification, regulatory supplements, or customer approval.

Are there Paragraph IV challenges, Orange Book listings, or biosimilar risks for PET?

No conventional Paragraph IV or Orange Book exposure attaches to PET packaging itself. Paragraph IV litigation concerns patents listed for approved drug products, not packaging polymers in isolation.

PET also has no biosimilar risk. Biosimilar competition affects biologic drug products and can indirectly influence packaging demand if lower prices reduce spending on premium container systems. It does not create a direct patent challenge to PET.

PET packaging can be implicated in drug litigation when a formulation patent, method-of-use patent, or drug-device combination patent covers a specific delivery system. That exposure is product-specific and should not be attributed to PET resin generally.

What is the commercial outlook for PET in pharmaceuticals?

The base-case outlook is moderate volume growth with continued margin differentiation.

Period	Expected market condition	Financial implication
Near term	Stable pharmaceutical demand, volatile resin inputs	Volume resilience, margin pressure for commodity producers
Medium term	More recycled-content requirements and regional sourcing	Higher qualification spending and selective pricing power
Longer term	Greater use of sustainable packaging and high-barrier systems	Growth for specialized converters; pressure on undifferentiated resin

The strongest commercial position is likely to remain with suppliers that combine PET materials with validated pharmaceutical packaging, regulatory support, and sustainable-content solutions. Commodity resin exposure alone provides weaker earnings visibility.

Key Takeaways

• PET is primarily a pharmaceutical packaging polymer, not a conventional pharmaceutical excipient.
• The main applications are bottles and containers for tablets, capsules, liquids, OTC products, and consumer health products.
• PET packaging is assessed through container-closure, compatibility, migration, and extractables and leachables requirements.
• The FDA does not grant blanket approval for every PET grade and every pharmaceutical formulation.
• Direct pharmaceutical PET revenue is rarely disclosed, so market estimates must separate resin, conversion, and finished packaging value.
• Commodity PET producers remain exposed to global overcapacity and petrochemical input costs.
• Pharmaceutical packaging converters can achieve stronger pricing power through validated systems, regulatory documentation, and customer switching costs.
• rPET adoption is increasing, but pharmaceutical qualification requirements will limit rapid substitution of virgin PET.
• PET has no direct Orange Book, Paragraph IV, or biosimilar exposure.
• The most durable competitive barriers are manufacturing qualification, packaging validation, supply reliability, and specialized designs rather than broad PET composition patents.

FAQs About Polyethylene Terephthalate in Pharmaceutical Packaging

Is PET safe for pharmaceutical bottles?

PET can be suitable for pharmaceutical bottles when the complete container-closure system is compatible with the formulation and passes applicable extractables, leachables, stability, and closure-integrity evaluations.

Is PET listed in the FDA Inactive Ingredient Database?

PET is generally evaluated as a packaging material rather than as an inactive ingredient incorporated into the drug formulation. The FDA Inactive Ingredient Database is therefore not the principal source for assessing PET bottle suitability.

Is recycled PET used for pharmaceutical packaging?

Recycled PET is used in some healthcare and pharmaceutical packaging applications, but adoption depends on purity, traceability, contamination controls, extractables and leachables data, and the requirements of the drug product.

Which is better for pharmaceutical bottles, PET or HDPE?

Neither material is universally superior. PET provides transparency, stiffness, and impact resistance. HDPE often provides stronger moisture protection. The formulation, shelf-life target, and packaging line determine the appropriate material.

Can PET packaging create patent protection for a drug?

PET packaging alone usually does not create exclusivity for the drug. Patent protection may arise from a specific drug-device combination, delivery system, bottle configuration, or packaging process, but those rights are separate from the basic PET polymer.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

2. U.S. Food and Drug Administration. (2024). Container closure systems for packaging human drugs and biologics: Guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. U.S. Department of Health and Human Services.

4. United States Pharmacopeial Convention. (2024). USP-NF General Chapter <661.1>: Plastic materials of construction. United States Pharmacopeial Convention.

5. United States Pharmacopeial Convention. (2024). USP-NF General Chapter <661.2>: Plastic packaging systems for pharmaceutical use. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 177.1630: Polyethylene phthalate polymers. Electronic Code of Federal Regulations.